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During the last three decades, the pharmaceutical sector has shown an explosive growth all 
over the world. After eatables, cosmetics and textile, pharmaceutical are rapidly surging ahead to 
become the third largest industry in several developed countries, thanks to health awareness 
propagated by World Health Organization (WHO).
1
 India has not lagged behind. Indian 
Pharmaceutical Industry in spite of tough competition, have got entrenched in eastern, mid-eastern 
and in several western markets. Some of our pharmaceutical multinationals have already acquired an 
edge over several well established foreign multinationals. Our pharmaceutical export revenue is 
increasing year after year. The researcher has highlighted the issue concerning the heath issues of the 
people of developing nations like India as a challenge for 21
st
 century.  
INTRODUCTION 
In India more than 40 thousand pharmaceuticals manufactures of all grades are flooding the 
market with nearly 50 thousand patent as well as 200 thousand generic drugs and formulation of all 
types.
2
 This number is rapidly increasing every year. The global market harshly enforces 
specifications and quality control in all respects, retail dispensing, pricing and presentation etc. 
according to the norms laid down by the respective authorities concerned. The prices of 
pharmaceuticals/ medicines is the single most pinching problem which makes them out of reach for 
those who need them the most. It is an irony of paucity in the midst of plenty. About 35-40 percent of 
Indians are below the poverty line, 50% are in middle income group and only 10% are different.
3
 No 
strip of ten capsules is sold less than Rs. 50-60 making it hardly affordable for 70-80 percent of 
                                                          
 Assistant Professor, School of Law, Shoolini University of Biotechnology and Management Sciences, Solan, HP 
1
 Dr. (Brig.) M.L. Katria, “Drugs Aplenty, But not for common man,” Published in Oped Health, The Tribune, Dated 
  18
th




 Ibid  
 
 
An International Refereed e-Journal 
                        (Peer Reviewed, Refereed & Open Access, Index, Journal of Law) 
Web: www.lrdjournal.com,    Email: journal1257@gmail.com 
 
[64] 
Vol. 2, Issue-I 
Sep. 2017 
Indians. Thus, the Indian pharmaceutical market in spite of supervision and control by the Centre as 
well as State authorities concerned, needs several reforms to suit the Indian consumers. 
Today one of the major challenges the world has to attend is the health issues of the public. 
People suffer from a wide range of diseases that depend upon age, territory, social conditions, 
economic status and genetic constitution. A disease does not know rich or poor. The diseases may be 
curable or incurable. Even in the case of diseases that are curable, if they are not treated with proper 
medicine in time ultimately lead to death of the patient and the very existence of human race would 
be a question. Availability, access and affordability to medicine are three different dimensions in a 
patient’s life. Medicines may be available yet people may not be able to access it. Strategies for 
procuring reliable and affordable supplies of medicines are important in determining how easy or 
difficult it is for patient in poorer countries to receive the treatment they need.
4
 WHO has listed some 
of the causes that may lead to death. These include diseases like, lower respiratory infection-6.1%, 
diarrhea diseases- 4.3%, HIV/AIDS -3.1%, ischemic heart diseases-12.8%, malaria stroke and other 
cerebrovascular-10:8%, tuberculosis-2.4%, neonatal infection, chronic pulmonary diseases- 5.8%, 
diabetes mellitus- 2.2%, hypertensive heart disease - 2.4%.
5
 The National Rural and Health Mission 
and health insurance schemes for those below poverty line have not made any significant 
improvement in the healthcare. 
Under the present multilateral trading system certain factors have a bearing on access to 
medicines includes- prices of medicines, intellectual property rights, procurement and competition, 
policies , taxes and tariffs and regulation to ensure the quality, quantity, safety, availability and 
efficacy of medicines. This chapter focuses on a study of pharma industry with special reference to 
kinds and quantity of drugs they manufacture, health care market, role of Research and Development 
(R & D), clinical trials for ensuring safety of drugs that are made available, threats and weakness of 
pharma industry, the government initiatives for the development of pharma industry and related 
issues. 
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INDIAN HEALTHCARE SEGMENT 
 The Indian consumer health care segment in pharmaceuticals is currently estimated at above 
US $ 3 Billion and is expected to grow at 14 to 16% to become US $ 14 to 18 Billion by 2020.
6
 
Access to essential medicines is a part of the fulfillment of the right to the highest attainable 
standards of health. Thus the price and availability of medicines to those who need them are crucial 
factors. The global OTC drugs have been increasing due to aggressive efforts of global 
pharmaceutical companies and the consumers showing interest on purchasing of OTC drugs. Some 
examples in India are Dabur Honitus Lozenges, Cough syrups, Vicks Vaporup, Zandu Balm, Iodex, 
Moov, Cough drops and Lozenges etc.
7
 These products do not require a drug license thus can be sold 
by non-chemists. India's pharma consumers rely on self-medication thus making OTC drug section 
economically strong and also forming a major segment of expenditure in health care. OTC drugs 
have shown growth in cough and cold formulation, gastrointestinal, analgesics and dermatologicals.
8
 
It also includes vitamins, minerals, artificial sweeteners, emergency contraceptive pills and 
nutritional supplements. Even anti-obesity drugs and anti-stress candies are emerging as OTC 
medicines in India. 
 In India Drugs and Cosmetics Act, 1940
9
 deals with import, manufacture and distribution of 
drugs in India. The primary objective of the act is to ensure that the drugs and cosmetics sold in India 
are safe, effective and conform to state quality standards. The Government of India is now showing 
considerable interest to extend the list of drugs which can be sold outside pharmacies and expansion 
of the list would substantially increase the potential market opportunity. Another major sector in 
India's health care segment expenditure is on ' Ayurvedic medicines' and 'traditional medicines' 
Ayurvedic medicines because of their plant based natural ingredients are highly preferred in a 
country like ours who have been cherishing the age old traditional knowledge. 
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Traditional Medicines 
The Indian systems of medicines and Homeopathy use mainly plant materials for the 
preparation of drugs
10
 8000 plants are stated to have medicinal properties although 500 of them are 
most commonly used. World's herbal medicines market is worth Rs. 7,050 crores dollars annually 
with approx. 10-12% growth rate.
11
 Indian medicines value Rs. 1.2 lakh crore and out of it 20% are 
natural medicines. Apart for the allopathic sector these medicinal products forms the backbone of 
Indian health care segment. Alovera, amla, ashwagandha, brahmi, garlic, jinzer, tulsi, satavari, 
chandan, turmeric, are a few plant products having great traditional medicinal values.
12
 In India the 
Department of AYUSH was formed w.e.f. 9
th
 November, 2014. It stand for Ayurueda, Yoga 
Naturopathy, Unani, Siddha and Homeopathy.
13
 It is under the department of Health and Family 
welfare, proposed with developing education and research in ayurveda an alternative medicine 
science. It is committed to infuse the wisdom of traditional medicine with methodologies of modern 
medicine. 
ACCESS TO MEDICINE (ATM) 
Access to medicine is a key issue for a country like India having diversified economic strata 
in its domestic market. The compliance with the Agreement of Trade Related Aspects of Intellectual 
Property Rights (TRIPS) has made this issue even more contentious. Price has a decisive impact on 
access to medicines. Access to medicines are mainly influenced by many factors like remoteness, 
lack of staff poor procurement practices and delivery systems, high level of patient illiteracy, national 
policies on protecting local industries, the level of competition between pharmaceutical 
manufactures, price regulation polices etc. 
Francis Gurry Director-General WIPO raised the question of balance between creation i.e. 
incentive to create and on the other hand the diffusion of the social benefit of the innovation or the 
new creation.
14
 Poverty is the greatest hurdle in accessing medicines. Apart from poverty the other 
factors related with access to medicine are increase of people's average life expectancy, cost of living 
                                                          
10
 Supra note 17 
11




 www.Indianmedicine.nic.in (Visited on 25/06/2016) 
14
 "Measuring medicine prices, availability and price components, 2
nd
 Ed., World Health Organization, (2008),  p. 1 
 
 
An International Refereed e-Journal 
                        (Peer Reviewed, Refereed & Open Access, Index, Journal of Law) 
Web: www.lrdjournal.com,    Email: journal1257@gmail.com 
 
[67] 
Vol. 2, Issue-I 
Sep. 2017 
standard, emerging of new diseases, increasing resistance of existing drugs, exploitation of 
unpatented and traditional medicines etc.
15
 The World Health Organization (WHO) indicates that 
one-third i.e. 30- 37% of the world i.e. 1.3 to 2.1 billion people lacks regular access to essential 
medicines. 
16
 Poverty affects purchasing power, and the inability of the poor to pay for medicines 
which reduces effective demand. Poverty in India is widespread with nation estimate to have third of 
the world’s poor.
17
 In 2011, World Bank stated, 32.7% of the total people of India fall below the 
international poverty line of US $ 1.25 per day. While 68.7% lives on less than US $ 2 per day.
18
 Of 
4.8 billion people in developing countries, 2.7 billion live on less than US $ 2 per day.
19
 Economic 
status is a very important determinate of health status. Although the patent law regime is one of the 
causes for higher prices of drugs and medicines but both national and international laws have 
incorporated sufficient provisions that attempts to protect the public interest. Apart from this, various 
other laws, different modes adopted by the companies, alternative sources of medicines and 
government policies tend to assure that medicines are capable of being accessed by the poor. 
INDIAN PHARMACEUTICAL INDUSTRY 
The Indian Pharmaceutical Industry is one of the most vibrant knowledge driven industries in 
India. It has witnessed spectacular growth over the past three decades.
20
 Currently, over 90% of the 
modern medicine consumed in India is produced locally.
21
 The industry manufactures almost entire 
range of therapeutic products and is capable of producing raw materials for manufacturing a wide 
range of bulk drugs. It was estimated to be worth $ 7 Billion in 2003, growing at about 6 to 7% 
annually.
22
 The Indian pharma industry is ranked 4
th
 in terms of volume accounting for 8% of global 
output in terms of volume and ranked 13
th
 in terms of value.
23
 Rapid growth in this sector has been 
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largely due to three critical stages, mainly attributable to Indians socialist vision in 1960s and 1970s. 
Prior to the Act 1970, under the Patent and Designs Act, 1911, India had permitted product patents 
for the drugs which allowed the multinationals firms from developed countries, especially US, UK 
and Germany to dominate the domestic market for pharmaceuticals with a share of 85%.
24
 However, 
after the changes made in the form of Act of 1970, which recognized only process patent for the drug 
industry the share of multinational firms gradually declined over the years up to about 40% in 1999.
25
 
The Act of 1970 aimed to foster development of indigenous Indian pharmaceutical industry and to 
guarantee access to low cost drugs to the Indian public.  
The Patent Act, 1970, played a key role in the rapid growth of the sector. As per the Act, the 
local drug manufacturers were allowed to copy patented drugs and produce them through an 
alternative process resulting in cost effective so called generic medicines.
26
 Indian companies were 
able to market drugs within 3-4 years of their introduction in the global market, which otherwise 
would take more than 10 years, and that too at costs which were 2.5 to 10% of patented drugs. For 
instance, companies offered certain drugs to treat HIV positive cases at $140 per annum vis a vis at $ 
10,000 per annum charged by MNC'S.
27
 Indian drug companies which earlier produced only for 
domestic consumption have later on been capable of exporting medicines worth 16 thousands 
crores.
28
 In India, health care industry at present is worth $ 6.5 billion and has been expanding at a 
fairly high rate of 8-10 percent per annum.
29
 Exports of the Indian drugs have increased by nearly 30 
percent during the past 5 years and have already crossed $ 2 billion.
30
 
Till very recently, the lifesaving drugs in India were many times cheaper as compared to the 
prices in the developed countries. For instance, the antibiotic Ciprofloxacin (500 mg) costs Rs. 39.60 
for a pack of 10 in India while it costs Rs. 506.58 for the same quantity produced by a MNC like 
Bayer in India, Rs. 1548 in USA and Rs. 979.80 in UK. An Anti-cancer drug like Vinclastine (10mg) 
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costs Rs. 195 in India, Rs. 400 in Pakistan, Rs. 1743.22 in US and Rs. 976.35 in UK.
31
 The global 
market for generic drugs in 2009 was worth US$ 108 billion and the India pharma ranks 4
th
 in terms 
of generic production being 20% in terms of value.
32
 An India’s export of generic drugs is growing at 
a rate of 24% over the past four years. Exports to US rose to nearly 32% in 2014 to US $ 4.23 billion. 
India accounts for nearly 40% of generic drugs and over the counter products and 10% of finished 
dosages used in US.
33
 
 Indian Pharmaceutical Industry is the largest exporter of generic formulations in volume 15% 
of generics by volume are sold in USA. Over 8 million people and 30% of world requirement across 
the globe that receive anti-retrovials are from generic companies of India. Thus, every 5
th
 tablet, 
capsules and inject able in generic drugs category consumed anywhere in the world is manufactured 
in India.
34
 Generics will continue to dominate the market due to raising health care costs and patent 
products are likely to constitute 10% of the pie till 2015. US patent on many drugs expires by 2015 
resulting in reduction of price up to US $ 300 billion, of conventional and biopharmaceuticals and the 
consequent generic production market is estimated to grow at least 30-35%. 
CONCLUSION 
Generic companies are increasingly focusing on expanding presence in relatively under 
penetrate markets like France, Spain and Italy. The increasing sales of generic medicines in India 
continue growth in chronic diseases and therapies especially in rural populated markets. Similarly, 
generic versions of biological products are also produced by Indian companies. In this regard Indian 
Bio pharma is placed as the fourth largest bio-generic producing country in the world. 
NPPA has fixed the ceiling prices in respect of 440 medicines upto 30
th
 June 2014 and 
brought under control prices of 652 drug formulations out of 68 various types of drug formulations 
from 348 drugs listed in NLEM 2011 under DPCO 2013. 
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Nonetheless, the NPPP 2012 and DPCO 2013 are silent on exorbitantly priced patented 
medicines of MNC's. Price control does not make drugs accessible to the poor or needy people. Price 
control is justifiable only under extraordinary circumstances like emergency, epidemic or where a 
monopoly situation exists. The highly competitive scenario too does not allow companies to reduce 
drug prices below certain levels and continue to maintain scale and profits. Indian Pharmaceutical 
Industry is making all efforts to ensure availability of medicines and taking India to a leadership 
position in Global Pharmaceutical. Government of India is taking all necessary steps in supporting 
the Indian pharma industry by ensuring adequate availability of high skilled and trained manpower, 
rationalizing forces, providing various fiscal and non-fiscal incentives for R&D and minimal price 
control. 
 
 
